December 18, 2017 Press release - Regulatory Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
December 11, 2017 Press release - Regulatory Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
October 12, 2017 Press release - Regulatory Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer
October 3, 2017 Press release - Regulatory Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
September 25, 2017 Press release - Regulatory Targovax granted US Patent for mutant-RAS neoantigen platform lead products
June 6, 2017 Press release - Regulatory Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
May 10, 2017 Press release - Regulatory Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
April 20, 2017 Press release - Regulatory Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
April 6, 2017 Press release - Regulatory Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
March 22, 2017 Press release - Regulatory Targovax ASA: The board of directors of Oslo Stock Exchange approves transfer of Targovax ASA to the main list
March 17, 2017 Press release - Regulatory Targovax ASA applies for transfer to Oslo Stock Exchange main list
February 2, 2017 Press release - Regulatory Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
January 5, 2017 Press release - Regulatory Targovax announces appointment of Erik Digman Wiklund as CFO
